1. Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells
    Peng Wang et al, 2019, Cell Metabolism CrossRef
  2. Recent progress in TGF-β inhibitors for cancer therapy
    Cheng-Yi Huang et al, 2021, Biomedicine & Pharmacotherapy CrossRef
  3. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
    D. Ciardiello et al, 2020, Annals of Oncology CrossRef
  4. Targeting the TGFβ pathway for cancer therapy
    Cindy Neuzillet et al, 2015, Pharmacology & Therapeutics CrossRef
  5. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model
    Camila Leonel et al, 2017, Journal of Mammary Gland Biology and Neoplasia CrossRef
  6. Targeting TGF-β Signaling for Therapeutic Gain
    Rosemary J. Akhurst, 2017, Cold Spring Harbor Perspectives in Biology CrossRef
  7. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo
    Xi-Ran He et al, 2017, Journal of Ethnopharmacology CrossRef
  8. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
    Katrin Moses et al, 2016, Seminars in Immunology CrossRef
  9. TGFβ signaling networks in ovarian cancer progression and plasticity
    Asha Kumari et al, 2021, Clinical & Experimental Metastasis CrossRef
  10. Reverting Immune Suppression to Enhance Cancer Immunotherapy
    Bella S. Guerrouahen et al, 2020, Frontiers in Oncology CrossRef
  11. Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer
    Michiko Harao et al, 2015, BioDrugs CrossRef
  12. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
    Xianhui Chen et al, 2021, Molecular Therapy - Oncolytics CrossRef
  13. Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
    Brian T. Welsh et al, 2021, International Journal of Toxicology CrossRef
  14. Mammary Gland Involution Provides a Unique Model to Study the TGF-β Cancer Paradox
    Qiuchen Guo et al, 2017, Journal of Clinical Medicine CrossRef
  15. TGFβ biology in cancer progression and immunotherapy
    Rik Derynck et al, 2021, Nature Reviews Clinical Oncology CrossRef
  16. Cancer Immunology
    Diane Tseng et al, 2020, Abeloff's Clinical Oncology CrossRef
  17. Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives
    Christopher J. Hanley et al, 2021, Oncotarget CrossRef
  18. Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
    Masaki Terabe et al, 2017, OncoImmunology CrossRef
  19. Harnessing Carcinoma Cell Plasticity Mediated by TGF-β Signaling
    Xuecong Wang et al, 2021, Cancers CrossRef
  20. Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate
    Aaron Kunamalla et al, 2016, Circulation Research CrossRef
  21. The TGFβ and Androgen Receptor Signaling Pathways Converge to Support Anoikis Resistance in Triple Negative Breast Cancer
    Emmanuel Rosas et al, 2021, Anoikis CrossRef